Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 67

1.

Engineering Enhanced Protein Disaggregases for Neurodegenerative Disease.

Jackrel ME, Shorter J.

Prion. 2015 Mar 4:0. [Epub ahead of print]

PMID:
25738979
2.

The hsp104 N-terminal domain enables disaggregase plasticity and potentiation.

Sweeny EA, Jackrel ME, Go MS, Sochor MA, Razzo BM, DeSantis ME, Gupta K, Shorter J.

Mol Cell. 2015 Mar 5;57(5):836-49. doi: 10.1016/j.molcel.2014.12.021. Epub 2015 Jan 22.

PMID:
25620563
3.

Isolating potentiated Hsp104 variants using yeast proteinopathy models.

Jackrel ME, Tariq A, Yee K, Weitzman R, Shorter J.

J Vis Exp. 2014 Nov 11;(93):e52089. doi: 10.3791/52089.

PMID:
25407485
4.

Suramin inhibits Hsp104 ATPase and disaggregase activity.

Torrente MP, Castellano LM, Shorter J.

PLoS One. 2014 Oct 9;9(10):e110115. doi: 10.1371/journal.pone.0110115. eCollection 2014.

5.

Specific aromatic foldamers potently inhibit spontaneous and seeded Aβ42 and Aβ43 fibril assembly.

Seither KM, McMahon HA, Singh N, Wang H, Cushman-Nick M, Montalvo GL, DeGrado WF, Shorter J.

Biochem J. 2014 Nov 15;464(1):85-98. doi: 10.1042/BJ20131609.

6.

Potentiated Hsp104 variants suppress toxicity of diverse neurodegenerative disease-linked proteins.

Jackrel ME, Shorter J.

Dis Model Mech. 2014 Oct;7(10):1175-84. doi: 10.1242/dmm.016113. Epub 2014 Jul 25.

7.

A cellular system that degrades misfolded proteins and protects against neurodegeneration.

Guo L, Giasson BI, Glavis-Bloom A, Brewer MD, Shorter J, Gitler AD, Yang X.

Mol Cell. 2014 Jul 3;55(1):15-30. doi: 10.1016/j.molcel.2014.04.030. Epub 2014 May 29.

PMID:
24882209
8.

Reversing deleterious protein aggregation with re-engineered protein disaggregases.

Jackrel ME, Shorter J.

Cell Cycle. 2014;13(9):1379-83. doi: 10.4161/cc.28709. Epub 2014 Apr 2.

PMID:
24694655
9.

Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events.

Jackrel ME, DeSantis ME, Martinez BA, Castellano LM, Stewart RM, Caldwell KA, Caldwell GA, Shorter J.

Cell. 2014 Jan 16;156(1-2):170-82. doi: 10.1016/j.cell.2013.11.047.

10.
11.

Conserved distal loop residues in the Hsp104 and ClpB middle domain contact nucleotide-binding domain 2 and enable Hsp70-dependent protein disaggregation.

Desantis ME, Sweeny EA, Snead D, Leung EH, Go MS, Gupta K, Wendler P, Shorter J.

J Biol Chem. 2014 Jan 10;289(2):848-67. doi: 10.1074/jbc.M113.520759. Epub 2013 Nov 26.

12.

Hsp104 suppresses polyglutamine-induced degeneration post onset in a drosophila MJD/SCA3 model.

Cushman-Nick M, Bonini NM, Shorter J.

PLoS Genet. 2013;9(9):e1003781. doi: 10.1371/journal.pgen.1003781. Epub 2013 Sep 5.

13.

Fission yeast does not age under favorable conditions, but does so after stress.

Coelho M, Dereli A, Haese A, Kühn S, Malinovska L, DeSantis ME, Shorter J, Alberti S, Gross T, Tolić-Nørrelykke IM.

Curr Biol. 2013 Oct 7;23(19):1844-52. doi: 10.1016/j.cub.2013.07.084. Epub 2013 Sep 12.

14.

Stress granules as crucibles of ALS pathogenesis.

Li YR, King OD, Shorter J, Gitler AD.

J Cell Biol. 2013 Apr 29;201(3):361-72. doi: 10.1083/jcb.201302044. Review.

15.

Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS.

Kim HJ, Kim NC, Wang YD, Scarborough EA, Moore J, Diaz Z, MacLea KS, Freibaum B, Li S, Molliex A, Kanagaraj AP, Carter R, Boylan KB, Wojtas AM, Rademakers R, Pinkus JL, Greenberg SA, Trojanowski JQ, Traynor BJ, Smith BN, Topp S, Gkazi AS, Miller J, Shaw CE, Kottlors M, Kirschner J, Pestronk A, Li YR, Ford AF, Gitler AD, Benatar M, King OD, Kimonis VE, Ross ED, Weihl CC, Shorter J, Taylor JP.

Nature. 2013 Mar 28;495(7442):467-73. doi: 10.1038/nature11922. Epub 2013 Mar 3.

16.
17.

Hsp104 drives "protein-only" positive selection of Sup35 prion strains encoding strong [PSI(+)].

DeSantis ME, Shorter J.

Chem Biol. 2012 Nov 21;19(11):1400-10. doi: 10.1016/j.chembiol.2012.09.013.

18.

Operational plasticity enables hsp104 to disaggregate diverse amyloid and nonamyloid clients.

DeSantis ME, Leung EH, Sweeny EA, Jackrel ME, Cushman-Nick M, Neuhaus-Follini A, Vashist S, Sochor MA, Knight MN, Shorter J.

Cell. 2012 Nov 9;151(4):778-93. doi: 10.1016/j.cell.2012.09.038.

19.

Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models.

Armakola M, Higgins MJ, Figley MD, Barmada SJ, Scarborough EA, Diaz Z, Fang X, Shorter J, Krogan NJ, Finkbeiner S, Farese RV Jr, Gitler AD.

Nat Genet. 2012 Dec;44(12):1302-9. doi: 10.1038/ng.2434. Epub 2012 Oct 28.

20.

RNA-Binding Proteins in Amyotrophic Lateral Sclerosis and Neurodegeneration.

Ugras SE, Shorter J.

Neurol Res Int. 2012;2012:432780. doi: 10.1155/2012/432780. Epub 2012 Apr 19.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk